IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma
Acupuncture Use in BC Predicted by Social Determinants of Health
Variability Found in PROs, Gene Expression During AML Induction Chemo
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported